high mobility group nucleosome binding domain 1 pseudogene 2Genealiases: HMG14P · HMGN1L2
Q-omics provides the consensus-scored HMGN1P2 profile across patient tissues and cancer cell-line models. HMGN1P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, HMGN1P2 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, HMGN1P2 RNA expression shows 8,609 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, BLCA, and THYM as cancer lineages where HMGN1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P2 survival associations across molecular data types. HMGN1P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P2 RNA expression–survival associations across cancer types. High HMGN1P2 expression shows unfavorable associations in DLBC, CHOL, READ and LUAD, but favorable associations in BRCA and BLCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for HMGN1P2 RNA expression.
This table summarizes HMGN1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P2 shows higher tumor expression in BLCA, KICH, PRAD, HNSC and KIRC. The BLCA box plot shows higher HMGN1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.350, t-test p = .020).
This table shows molecular features associated with HMGN1P2 in patient tissues and cancer cell lines. In patient samples, HMGN1P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
